Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study * Male and female participants at least 18 years of age at the time of signing the ICF * Histologically or cytologically confirmed locally advanced unresectable or metastatic intrahepatic cholangiocarcinoma; at least one intrahepatic lesion must be present * Radiographically measurable or evaluable disease by CT or MRI per RECIST v1.1 criteria * ECOG performance status ≤1 * Body weight \>30 kg * Must have a life expectancy of at least 12 weeks * Participants must have adequate marrow function as defined below: * Hemoglobin ≥9.0 g/dL * Absolute neutrophil count (ANC) ≥1.0 × 109 /L * Platelet count ≥75 × 109/L * Participants must have adequate renal function as defined below: * Serum creatinine ≤ 1.5 mg/dL OR * Measured creatinine clearance (CL) \>40 mL/min or Calculated creatinine CL\>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance * Participants must have adequate hepatic function as defined below: * Bilirubin ≤1.5 x ULN * ALT ≤ 2.5 x ULN unless liver metastases are present, in which case it must be ≤5x ULN * AST ≤ 2.5 x ULN unless liver metastases are present, in which case it must be ≤5x ULN * This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or …